HMG / Menotropins

ID: hmg_menotropins

Aliases: HMG, human menopausal gonadotropin, menotropins, Menopur

Type: compound

Route/form: subcutaneous injection in labelled menotropin products

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_trial, label, meta_analysis, review

Linked sources: 4

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• FSH activity
• LH activity
• gametogenesis and fertility induction

Optimization domains

• fertility
• hormones
• reproductive endocrinology
• pct discussion
• spermatogenesis
• on cycle support

Research basis

• HMG/menotropins are relevant when the endpoint is spermatogenesis and testicular development because they supply FSH/LH activity rather than relying only on upstream pituitary signaling.
• Systematic-review and HH treatment data support gonadotropin-based induction/restoration in selected male hypogonadotropic-hypogonadism contexts.
• Optimization framing should put HMG next to hCG/enclomiphene for fertility preservation or recovery, not direct anabolic performance.

Limits, risks, and missing evidence

• HMG is not a casual PCT shortcut or standalone testosterone-maximization tool.
• Cost, injections, monitoring, estradiol/testosterone balance, semen outcomes, and diagnosis matter.
• Benefits are most defensible in suppressed or deficient gonadotropin contexts, not in eugonadal men seeking extra performance.

Risk flags

• hpg axis
• fertility context
• injectable
• medical supervision

Linked papers, labels, and reviews

1. DailyMed label: Menopur (menotropins for injection)
   label / dailymed_menopur_label
   Human menopausal gonadotropin label context.
2. Endotext: Hypogonadotropic hypogonadism and gonadotropin therapy
   review / ncbi_endotext_hh_gonadotropin_therapy
   Clinical review explaining pulsatile GnRH versus gonadotropin therapy and fertility endpoints.
3. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis
   meta_analysis / pubmed_hmg_puberty_induction_meta_2024
   Systematic review/meta-analysis relevant to FSH/LH-containing gonadotropin therapy and testicular development in male HH.
4. Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
   human_trial / pmc_hmg_gnrh_spermatogenesis_hh_2019
   Human HH comparison of pulsatile GnRH and HCG/HMG injection protocols for spermatogenesis-oriented endpoints.